Insilico Medicine has expanded its Science MMAI Gym, a large-scale training and benchmarking platform for artificial intelligence, with the launch of three public leaderboard portals designed to evaluate AI performance across scientific research and drug discovery. Positioned as both a training environment and benchmarking system, MMAI Gym enables the development of domain-specific AI models while rigorously assessing their capabilities on real-world tasks.

The newly launched benchmark categories include ScienceAI Bench, which evaluates general scientific reasoning across disciplines such as biology, chemistry, and materials science; the Drug Discovery Benchmark (DDB), focused on end-to-end pharmaceutical R&D tasks; and Insilico Bench, a proprietary suite targeting complex and emerging scientific challenges. Together, these benchmarks draw from both curated industry datasets and proprietary, experimentally grounded data, enabling multi-dimensional evaluation across more than 200 tasks.

The platform reflects a broader shift toward standardized, scalable evaluation of scientific AI systems. Previous results from Insilico demonstrate that models trained within MMAI Gym can achieve up to tenfold performance improvements on key drug discovery benchmarks. In collaboration with Liquid AI, Insilico also developed a compact foundation model that achieved state-of-the-art performance across multiple drug discovery tasks, with findings presented at ICLR 2026.

By integrating training, benchmarking, and public evaluation, MMAI Gym aims to accelerate the adoption of reliable, high-performance AI systems across pharmaceutical research and beyond.